AstraZeneca (NASDAQ:AZN) Stock Acquired Rep. Julia Letlow

Representative Julia Letlow (R-Louisiana) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on January 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on December 8th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Pinterest (NYSE:PINS) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Mettler-Toledo International (NYSE:MTD) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Icon Energy (NASDAQ:ICON) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 12/8/2025.

AstraZeneca Stock Performance

Shares of AZN opened at $93.99 on Friday. The company has a market capitalization of $291.51 billion, a PE ratio of 31.23, a PEG ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The company’s 50 day moving average price is $91.33 and its 200 day moving average price is $82.58. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $96.51.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The company had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same quarter last year, the business posted $2.08 EPS. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. Research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Morgan Stanley reaffirmed an “overweight” rating and set a $103.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 3rd. Barclays reissued an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

Hedge Funds Weigh In On AstraZeneca

Institutional investors have recently modified their holdings of the company. Primecap Management Co. CA grew its stake in AstraZeneca by 1.3% in the 2nd quarter. Primecap Management Co. CA now owns 41,200,091 shares of the company’s stock valued at $2,879,062,000 after buying an additional 538,606 shares during the last quarter. Bank of America Corp DE boosted its holdings in AstraZeneca by 4.7% during the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after acquiring an additional 1,461,786 shares during the period. Franklin Resources Inc. grew its position in shares of AstraZeneca by 0.9% in the second quarter. Franklin Resources Inc. now owns 21,298,394 shares of the company’s stock valued at $1,488,332,000 after purchasing an additional 196,401 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of AstraZeneca by 2.3% in the third quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock worth $1,623,604,000 after purchasing an additional 466,745 shares during the period. Finally, Jennison Associates LLC increased its stake in shares of AstraZeneca by 15.2% in the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock worth $850,255,000 after purchasing an additional 1,605,133 shares during the period. Institutional investors own 20.35% of the company’s stock.

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.